Swedish Orphan Biovitrum AB (publ) (FRA:B6E)

Germany flag Germany · Delayed Price · Currency is EUR
30.14
-0.48 (-1.57%)
Last updated: Dec 4, 2025, 8:34 AM CET
12.88%
Market Cap 10.78B
Revenue (ttm) 2.52B
Net Income (ttm) 1.18M
Shares Out n/a
EPS (ttm) 0.00
PE Ratio 9,164.64
Forward PE 18.49
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 8
Open 30.14
Previous Close 30.62
Day's Range 30.14 - 30.14
52-Week Range 22.40 - 31.00
Beta n/a
RSI 60.24
Earnings Date Feb 5, 2026

About FRA:B6E

Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocy... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1939
Employees 1,806
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol B6E
Full Company Profile

Financial Performance

In 2024, FRA:B6E's revenue was 26.03 billion, an increase of 17.65% compared to the previous year's 22.12 billion. Earnings were 3.89 billion, an increase of 61.27%.

Financial numbers in SEK Financial Statements

News

There is no news available yet.